Literature DB >> 1822959

Immunologic responses to repeated ivermectin treatment in patients with onchocerciasis.

C Steel1, A Lujan-Trangay, C Gonzalez-Peralta, G Zea-Flores, T B Nutman.   

Abstract

To assess the effect of ivermectin treatment on the immunologic status of individuals with onchocerciasis, 27 patients from Guatemala were studied before and at 6-month intervals during 2 years of repeated semiannual treatment with ivermectin. T cell proliferative responses to onchocercal antigen increased transiently by 6 months (mean stimulation index [SI] rising from 4.17 to 12.81) but returned to preivermectin levels thereafter. Changes in SI to nonparasite antigen paralleled those induced by parasite antigen. There were also significant decreases in levels of blood eosinophils, polyclonal IgG and IgE, parasite-specific IgG antibody, and IgG subclass antibodies by the end of the study. This study emphasizes the apparent long-term safety of ivermectin by demonstrating the absence of immunopathogenic responses induced by repeated ivermectin treatments.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1822959     DOI: 10.1093/infdis/164.3.581

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Filarial infection modulates the immune response to Mycobacterium tuberculosis through expansion of CD4+ IL-4 memory T cells.

Authors:  Soumya Chatterjee; Carolyn E Clark; Enrico Lugli; Mario Roederer; Thomas B Nutman
Journal:  J Immunol       Date:  2015-02-09       Impact factor: 5.422

Review 2.  Impact of filarial infections on coincident intracellular pathogens: Mycobacterium tuberculosis and Plasmodium falciparum.

Authors:  Simon Metenou; Subash Babu; Thomas B Nutman
Journal:  Curr Opin HIV AIDS       Date:  2012-05       Impact factor: 4.283

3.  Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy.

Authors:  C S Mai; D M Hamm; M Banla; A Agossou; H Schulz-Key; C Heuschkel; P T Soboslay
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

4.  Ivermectin-facilitated immunity in onchocerciasis; activation of parasite-specific Th1-type responses with subclinical Onchocerca volvulus infection.

Authors:  P T Soboslay; C G Lüder; W H Hoffmann; I Michaelis; G Helling; C Heuschkel; C M Dreweck; C H Blanke; S Pritze; M Banla
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

Review 5.  Helminth-Tuberculosis Co-infection: An Immunologic Perspective.

Authors:  Subash Babu; Thomas B Nutman
Journal:  Trends Immunol       Date:  2016-08-05       Impact factor: 16.687

6.  Ivermectin-facilitated immunity in onchocerciasis. Reversal of lymphocytopenia, cellular anergy and deficient cytokine production after single treatment.

Authors:  P T Soboslay; C M Dreweck; W H Hoffmann; C G Lüder; C Heuschkel; H Görgen; M Banla; H Schulz-Key
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

7.  Onchocerca volvulus-specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central Togo.

Authors:  Saskia I Johanns; Richard G Gantin; Bawoubadi Wangala; Kossi Komlan; Wemboo A Halatoko; Meba Banla; Potchoziou Karabou; Adrian Jf Luty; Hartwig Schulz-Key; Carsten Köhler; Peter T Soboslay
Journal:  PLoS Negl Trop Dis       Date:  2022-05-03

8.  Modelling exposure heterogeneity and density dependence in onchocerciasis using a novel individual-based transmission model, EPIONCHO-IBM: Implications for elimination and data needs.

Authors:  Jonathan I D Hamley; Philip Milton; Martin Walker; Maria-Gloria Basáñez
Journal:  PLoS Negl Trop Dis       Date:  2019-12-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.